Lava Therapeutics B.V.’s (NASDAQ:LVTX) lock-up period is set to end on Tuesday, September 21st. Lava Therapeutics B.V. had issued 6,700,000 shares in its IPO on March 25th. The total size of the offering was $100,500,000 based on an initial share price of $15.00. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Several equities analysts have commented on LVTX shares. Zacks Investment Research upgraded shares of Lava Therapeutics B.V. from a “sell” rating to a “hold” rating in a report on Wednesday, July 21st. SVB Leerink reduced their target price on shares of Lava Therapeutics B.V. from $26.00 to $24.00 and set an “outperform” rating for the company in a research report on Tuesday, August 17th.
LVTX opened at $5.95 on Tuesday. Lava Therapeutics B.V. has a twelve month low of $5.50 and a twelve month high of $17.20. The business’s 50-day moving average price is $6.87.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Davidson Kempner Capital Management LP bought a new stake in Lava Therapeutics B.V. during the first quarter worth about $30,000. Point72 Asset Management L.P. bought a new position in shares of Lava Therapeutics B.V. in the first quarter worth about $84,000. Geode Capital Management LLC bought a new position in shares of Lava Therapeutics B.V. in the second quarter worth about $141,000. Point72 Hong Kong Ltd bought a new position in shares of Lava Therapeutics B.V. in the first quarter worth about $142,000. Finally, Tudor Investment Corp Et Al bought a new position in shares of Lava Therapeutics B.V. in the first quarter worth about $298,000. 34.61% of the stock is owned by institutional investors and hedge funds.
About Lava Therapeutics B.V.
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.
Featured Article: What can cause a stock to outperform?
Receive News & Ratings for Lava Therapeutics B.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lava Therapeutics B.V. and related companies with MarketBeat.com's FREE daily email newsletter.